Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

GE25-6600-25

Genomiphi™ Hy Kit

Cytiva 25-6600-25, sufficient for 1000 reactions

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Code UNSPSC :
41116006
Nomenclature NACRES :
NA.55

Utilisation

sufficient for 1000 reactions

Fabricant/nom de marque

Cytiva 25-6600-25

Conditions d'expédition

dry ice

Température de stockage

−70°C

Description générale

Illustra GenomiPhi™ HY DNA Amplification Kit offers highly efficient and representative whole-genome amplification with 40 to 50 μg yield from nanogram amounts of DNA sample.

Application

illustra™ GenomiPhi™ HY DNA Amplification Kit is part of the Phi29 DNA polymerase family of products from Cytiva. It contains all of the components necessary for midi-scale whole genome amplification by isothermal strand displacement amplification.

Amplification is highly uniform over the entire genome so that locus representation remains extremely close to the original DNA sample. Furthermore, amplification is carried out with very high fidelity due to Phi29 DNA polymerase proofreading activity.

The illustra™ GenomiPhi™ HY DNA Amplification Kit procedure is quick, simple and does not require a thermal cycler. A typical DNA yield of 40 to 50 μg DNA can be achieved in four h with little hands-on time. The average product length is over 10 kb. The starting material for GenomiPhi™ reactions can be purified DNA from any commercial kit or homebrew method, or a nonpurified cell lysate may be used. The kit was verified with DNA from various clinical samples including blood and buccal swabs.
GenomiPhi™ amplified DNA is suitable for various applications such as genotyping (SNP, STR, array CGH), cloning, sequencing, and DNA archiving.

Caractéristiques et avantages

  • Representative isothermal amplification of the whole genome.
  • No template-independent, background amplification product.
  • Outperforms PCR-based whole genome amplification techniques.
  • Quick and simple automation-friendly protocol; no thermal cycler required.
  • Yields high-quality DNA (e.g., for high-throughput genotyping, hybridization, and DNA archival).

Stockage et stabilité

Please be aware this product may be shipped 90 days before the expiration date. For more information on the batch specific expiration date, please contact technical service.
S-re the kit at -70°C. The enzyme mix must be s-red at -70°C; all other components may be s-red at -20°C Thaw components on ice and maintain at 0°C - 4°C during handling

Remarque sur l'analyse

To view the Certificate of Analysis for this product, please visit www.cytiva.com.

Informations légales

GenomiPhi
On packaging and insert:
For use only as licensed by Qiagen GmbH. and Cytiva. The Phi 29 DNA polymerase may not be re-sold or used except in conjunction with the other components of this kit. See US patent numbers 5,854,033, 6,124,120, 6,143,495, 6,323,009, 5,576,204, and equivalent patents and patent applications in other countries.
On container:
Subject to proprietary rights of Cytiva. May not be re-sold or used except with the other components of this kit. See US patent numbers 5,576,204, and equivalent patents and patent applications in other countries.
GenomiPhi is a trademark of Cytiva
illustra is a trademark of Cytiva

Code de la classe de stockage

12 - Non Combustible Liquids

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Enrico Tiacci et al.
Haematologica, 98(4), 635-639 (2013-01-26)
The BRAF-V600E mutation defines genetically hairy cell leukemia among B-cell leukemias and lymphomas. In solid tumors, BRAF-V600E is known to aberrantly activate the oncogenic MEK-ERK pathway, and targeted BRAF and/or MEK inhibitors have shown remarkable efficacy in clinical trials in
Jennifer Yen et al.
Genome biology, 14(10), R113-R113 (2013-10-24)
Melanoma is the most deadly form of skin cancer. Expression of oncogenic BRAF or NRAS, which are frequently mutated in human melanomas, promote the formation of nevi but are not sufficient for tumorigenesis. Even with germline mutated p53, these engineered
Jeffrey S McLean et al.
Proceedings of the National Academy of Sciences of the United States of America, 110(26), E2390-E2399 (2013-06-12)
The "dark matter of life" describes microbes and even entire divisions of bacterial phyla that have evaded cultivation and have yet to be sequenced. We present a genome from the globally distributed but elusive candidate phylum TM6 and uncover its
Nelson Ting et al.
Ecology and evolution, 2(3), 550-561 (2012-07-24)
It is difficult to predict how current climate change will affect wildlife species adapted to a tropical rainforest environment. Understanding how population dynamics fluctuated in such species throughout periods of past climatic change can provide insight into this issue. The
Ewen F Kirkness et al.
Genome research, 23(5), 826-832 (2013-01-04)
There is increasing evidence that the phenotypic effects of genomic sequence variants are best understood in terms of variant haplotypes rather than as isolated polymorphisms. Haplotype analysis is also critically important for uncovering population histories and for the study of
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique